Kristen Whitney, DO, FAAD, dermatologist at Allegheny Health Network, explored the intricate management of alopecia areata, ...

"Discover the new drug approval for alopecia areata and its significance. Dr. Dustin Portela, 208skindoc, focuses on skin ...

Most patients with alopecia areata treated with ritlecitinib who had a clinical response at week 24 sustained their response through week 48 with continued treatment, and nearly a third of those who ...

3 The authors wanted their article to raise awareness of JAK inhibitor use, effectiveness, and safety as potential alopecia ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

This Alopecia Areata Awareness Week, Rochester’s Maddison Staley has reflected on her journey with the condition as well as ...

The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by ...

Hair loss is considered widespread in recent years and has many degrees, as it begins with hair loss and may eventually lead to complete hair loss. There are many causes, the most important of which ...

Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...

Treatment with ritlecitinib sustained hair regrowth through week 48 in patients with alopecia areata (AA), and up to one third of nonresponders at week 24 also achieved responses by week 48.

A man suffering alopecia says he is being denied a groundbreaking new drug – despite it being approved. The daily pill, ...

but research was insufficient on the link between this treatment and alopecia areata, scarring alopecia, chemotherapy-induced alopecia, and telogen effluvium. Low-level laser/LED therapy (LLLT) for ...